Page 3 - Primary Analysis News Today

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

Numerous oral presentations highlighting data for tafasitamab, parsaclisib, ruxolitinib, pemigatinib, itacitinib and ponatinib to be highlighted during the Congress Incyte (Nasdaq:INCY) today announced

GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVI...

GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress The Janssen Pharmaceutical Companies of Johnson Johnson today announced primary results

/PRNewswire/ -- Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients...

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses ABBVie will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology Annual Meeting and the virtual European Hematology Association congress . “We are advancing discovery and innovation to improve on the standards of care for blood cancer treatment,” said Mohamed Zaki M.D., Ph.D., vice president and global head of onco...

NOVARTIS AG CHF0.50(REGD) Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177 Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO ...

The 2020 WCLC Presidential Symposium features: National Lung Cancer Screening Program in Taiwan: The TALENT Study (Abstract 3309), Pan-Chyr Yang, M.D., from the National Taiwan University College of Medicine, Taipei/Taiwan. International Tailored Chemotherapy Adjuvant Trial: ITACA (Abstract 1820) with Dr. Silvio Novello, University of Torino at San Luigi Gonzaga Hospital, Orbassano, Italy. Surgical and Clinical Outcomes with Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: LCMC3 Tri...